Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors
一项多中心、单臂、II期研究（CAP）评估了放射治疗联合脂质体伊立替康，随后进行卡瑞利珠单抗和抗血管生成治疗在晚期实体瘤中的疗效。
期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2023.1133689
Shen, Jie; Yan, Jing; Du, Juan; Li, Xiaoqin; Wei, Jia; Liu, Qin; Yong, Hongmei; Wang, Xiaolu; Chang, Xiaofeng; Ding, Zhou; Sun, Wu; Liu, Chenxi; Zhu, Sihui; Guo, Jingyi; Li, Huajun; Liu, Ying; Zhang, Wulou; Liu, Zonghang; Li, Rutian; Liu, Baorui
